

Tabuk Pharma to commercialize Moderna's COVID-19 vaccine in Saudi Arabia

14 June 2021 | News

Tabuk Pharmaceuticals will hold the marketing authorization for the Moderna COVID-19 vaccine in Saudi Arabia



Moderna, Inc. and Tabuk Pharmaceutical Manufacturing Company (a fully owned subsidiary of Astra Industrial Group), a leading Saudi pharmaceuticals company, have announced an agreement to commercialize the Moderna COVID-19 Vaccine and future variant-specific booster candidates in Saudi Arabia.

Under the terms of this agreement, Tabuk Pharmaceuticals will hold the marketing authorization for the Moderna COVID-19 vaccine in Saudi Arabia.

Beyond the Moderna COVID-19 Vaccine and Moderna's updated variant booster candidates, the agreement also gives Tabuk the possibility to discuss opportunities to distribute other Moderna mRNA products if authorized in the future.

"We welcome the opportunity to work with Tabuk Pharmaceuticals to bring the Moderna COVID-19 and potentially other Moderna mRNA products to Saudi Arabia in the future," said Corinne Le Goff, Pharm.D., M.B.A., Chief Commercial Officer of Moderna. "Together with our partners, we remain committed to delivering our vaccine to more populations around the world. We are pleased to have secured a new agreement to supply our COVID-19 vaccine and our updated variant booster vaccine candidate, if authorized, to Saudi Arabia for 2021 and 2022."